← All trials
NCT04846478
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- Apr 15, 2021
- Last posted
- Jul 13, 2021
- Enrollment
- 38
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
- PfizerCollaborator
- Epizyme, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.